Abbott Laboratories (NYSE:ABT) sees a 6.9% sales increase in Q2 2025 with an Adjusted EPS of $1.26, beating estimates. Biosimilars portfolio progressing with multiple launches expected in 2026. Executive VP sells shares, but FDA clears Medtronic’s MiniMed 780G system, providing an opportunity for Abbott to expand its diabetes technology.

With a market cap of $232.44 billion, Abbott Laboratories (NYSE:ABT) remains a strong choice for long-term, low-maintenance investors. The company, headquartered in Illinois since 1888, is a global healthcare leader offering a variety of medical devices, diagnostics, nutritional products, and established branded generic pharmaceuticals worldwide.

While ABT shows promise as an investment, certain AI stocks may offer greater upside potential with less downside risk. Consider exploring undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend. For more information, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale